Comparative Pharmacology
Head-to-head clinical analysis: INDO LEMMON versus NALFON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDO LEMMON versus NALFON.
INDO-LEMMON vs NALFON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Indomethacin is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits prostaglandin synthesis by blocking cyclooxygenase (COX-1 and COX-2) enzymes, reducing inflammation, pain, and fever.
Fenoprofen, a propionic acid derivative, nonselectively inhibits cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis.
Oral: 25-50 mg 2-3 times daily. Maximum daily dose: 200 mg.
NALFON (fenoprofen) 200-600 mg orally 3-4 times daily; maximum dose 3200 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 2-4 hours in healthy adults; may be prolonged in elderly or patients with hepatic impairment.
3-4 hours (terminal half-life in healthy adults; prolonged in elderly and hepatic impairment).
Renal excretion of unchanged drug and metabolites accounts for approximately 60% of elimination; biliary/fecal excretion accounts for approximately 40%.
Renal: 90% (mostly as glucuronide conjugates and unchanged drug; unchanged drug ~1-5%); Fecal: <5%; Biliary: negligible.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)